Stay updated on Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial

Sign up to get notified when there's something new on the Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    Revision: v3.5.0 was added. Revision: v3.4.3 was removed.
    Difference
    0.1%
    Check dated 2026-03-19T06:09:04.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The page's revision label updated from v3.4.2 to v3.4.3. No trial content or visible details appear to be altered.
    Difference
    0.1%
    Check dated 2026-03-12T02:22:18.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    Updates shown are revision dates for the study record (e.g., 2026-03-04, 2027-02) and related metadata. No substantive changes to study design, eligibility criteria, outcomes, or locations are indicated.
    Difference
    0.3%
    Check dated 2026-03-04T23:42:46.000Z thumbnail image
  4. Check
    26 days ago
    No Change Detected
  5. Check
    40 days ago
    Change Detected
    Summary
    Added site revision note 'Revision: v3.4.2'. Removed the operating-status notice about lapse in government funding and the earlier 'Revision: v3.4.1' note.
    Difference
    0.4%
    Check dated 2026-02-11T14:21:39.000Z thumbnail image
  6. Check
    47 days ago
    Change Detected
    Summary
    Added a government funding lapse notice at the top of the page and updated the site to version v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T10:39:53.000Z thumbnail image
  7. Check
    54 days ago
    Change Detected
    Summary
    Glossary visibility was added, the 'Last Update Submitted' label was standardized to 'Last Update Submitted that Met QC Criteria', a 'No FEAR Act Data' notice was included, and the revision was updated to v3.4.0 (replacing v3.3.4).
    Difference
    0.2%
    Check dated 2026-01-28T06:37:59.000Z thumbnail image

Stay in the know with updates to Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial page.